Yet the true potential of YAP/TAZ signaling inhibitors may be achieved by the combination with immune checkpoint inhibition, agents targeting additional oncogenic pathways, or the use of multimodal precision therapies co-targeting YAP/TAZ and their intrinsic and compensatory resistance pathways, thereby achieving durable cancer remission. This evidence concerns the gene WWTR1 and cancer.